Strategic Trust
Kelly CRISPR & Gene Editing Technology ETF
$3.27M
Avg Monthly Net Assets
$2.59M
Total Assets
$2K
Total Liabilities
$2.59M
Net Assets
Kelly CRISPR & Gene Editing Technology ETF is an Exchange-Traded Fund in Strategic Trust
,
based in Colorado,
United States of America.
The fund has one share class
and monthly net assets of $3.27M.
On January 24th, 2024 it reported 25 holdings, the largest
being CRISPR Therapeutics AG (14.7%), Beam Therapeutics Inc (13.4%) and Thermo Fisher Scientific Inc (9.9%).
Data provided by Fincoded.
Share Classes
| Name | Class/Contract ID | Exchange | Ticker | Monthly Returns (2 years) |
|---|---|---|---|---|
| Kelly CRISPR & Gene Editing Technology ETF | C000231237 | XNAS | XDNA |
Holdings
From latest NPORT-P, filed January 24th, 2024 for period ending November 30th, 2023.
Historic holdings data available from Fincoded.
| Name | Profile | Category | Country | Value $USD | # Shares | % of Fund |
|---|---|---|---|---|---|---|
| 2seventy bio Inc | Long | Equity-common | US | $45K | 25K | 1.75 |
| AbbVie Inc | Long | Equity-common | US | $104K | 728 | 4.01 |
| Agilent Technologies Inc | Long | Equity-common | US | $73K | 574 | 2.84 |
| Allogene Therapeutics Inc | Long | Equity-common | US | $78K | 33K | 3.00 |
| Beam Therapeutics Inc | Long | Equity-common | US | $346K | 12K | 13.36 |
| Biogen Inc | Long | Equity-common | US | $13K | 56 | 0.51 |
| Bristol-Myers Squibb Co | Long | Equity-common | US | $42K | 854 | 1.63 |
| Caribou Biosciences Inc | Long | Equity-common | US | $128K | 22K | 4.94 |
| CRISPR Therapeutics AG | Long | Equity-common | CH | $380K | 6K | 14.70 |
| Editas Medicine Inc | Long | Equity-common | US | $152K | 14K | 5.87 |
| First American Government Obligations Fund | Long | Short-term investment vehicle | US | $5K | 5K | 0.19 |
| First American Treasury Obligations Fund | Long | Short-term investment vehicle | US | $5K | 5K | 0.19 |
| Illumina Inc | Long | Equity-common | US | $31K | 308 | 1.21 |
| Intellia Therapeutics Inc | Long | Equity-common | US | $226K | 8K | 8.73 |
| Novartis AG | Long | Equity-common | CH | $79K | 812 | 3.07 |
| Poseida Therapeutics Inc | Long | Equity-common | US | $111K | 41K | 4.28 |
| Precision BioSciences Inc | Long | Equity-common | US | $22K | 63K | 0.86 |
| Prime Medicine Inc | Long | Equity-common | US | $156K | 22K | 6.05 |
| QIAGEN NV | Long | Equity-common | NL | $18K | 448 | 0.71 |
| Regeneron Pharmaceuticals Inc | Long | Equity-common | US | $35K | 42 | 1.34 |
| Sangamo Therapeutics Inc | Long | Equity-common | US | $44K | 102K | 1.69 |
| Sanofi SA | Long | Equity-common | FR | $85K | 910 | 3.28 |
| Thermo Fisher Scientific Inc | Long | Equity-common | US | $257K | 518 | 9.93 |
| Vertex Pharmaceuticals Inc | Long | Equity-common | US | $40K | 112 | 1.54 |
| Verve Therapeutics Inc | Long | Equity-common | US | $112K | 10K | 4.35 |
Address
Strategic Trust
7887 East Belleview Avenue
Suite 1100
Denver
Colorado
80111
United States of America
Directors
Ethan Powell
Matthew Patterson
Kevin Kelly
Transfer Agents
US Bancorp Fund Services LLC
Pricing Services
Intercontinental Exchange Inc.
Bloomberg L.P.
Custodians
US Bank NA
Shareholder Servicing Agents
N/A
Admins
US Bancorp Fund Services LLC
Brokers
Citadel Securities LLC